Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
978 28 |
Ultima descărcare din IBN: 2023-10-05 17:38 |
Căutarea după subiecte similare conform CZU |
616.12-008.46-007.2-053.1 (1) |
Pathology of the circulatory system, blood vessels. Cardiovascular complaints (975) |
SM ISO690:2012 PALII, Ina. Sindromul de insuficienţă cardiacă la copil (protocolul clinic standardizat pentru unitatea de primire urgenţe (UPU). In: Buletin de Perinatologie, 2018, nr. 4(80), pp. 46-51. ISSN 1810-5289. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletin de Perinatologie | ||||||
Numărul 4(80) / 2018 / ISSN 1810-5289 | ||||||
|
||||||
CZU: 616.12-008.46-007.2-053.1 | ||||||
Pag. 46-51 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Introduction: Heart failure (HF) syndrome is defined by the heart’s inability to produce cardiac output systemic or pulmonary for tissue needs or to support it under increased filling pressures. Aim: Studying Heart Failure Syndrome management in Children. Materials and Methods: The article is based on as medical publications from international literature and online material. Results: HR causes are divided into cardiac and extracardiac. The cardiac causes are structural abnormalities cardiac overload, left-right shunt, pressure overload, valvular insufficiency, but may also be “normal” in the regular heart - primary and secondary cardiomyopathy. Typical clinical manifestations in children may be tachypnea, alimentation problems (reflux, vomiting, loss of appetite), diaphoresis, and palpitations. The paraclinical evaluation includes routine analyzes and NT-proBNP, BNP, CK, MB fractions, cardiac troponins, C-reactive protein and functional and interventional tests (ECG standard 12 derivates, thoracic radiography + ICT, Echocardiography, Doppler-EcoCG). Treatment of acute HF includes diuretics, inotropic therapy - milrinone, dobutamine, epinephrine, digoxin, systemic vasodilators. Chronic HF therapy includes IECA (captopril, enalapril, ramipril, perindopril), angiotensin II receptor antagonists - losartan, beta – blockers, aldosterone antagonists. Conclusion: The key to achieving therapeutic success and implicitly the survival of the pediatric patient is the appreciation and treatment of the HF cause and gradual introduction of drug therapy according to the severity of clinical and paraclinical data |
||||||
Cuvinte-cheie heart failure, treatment, children. |
||||||
|